Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Hospital Transactions Held Steady in Q3:2018
Mergers and acquisitions in the Hospital sector held steady from the second to the third quarter, with 15 definitive agreements announced in each. Deal volume dropped 12% compared with the same quarter in 2017. The 15 deals announced in the second quarter made up 19% of the 80 deals announced in the previous 12 months. One factor behind the decline from the first quarter was the end of the announced divestitures made by some for-profit chains, particularly Community Health Systems (NYSE: CYH) and its spin-off, Quorum Health (NYSE: QHC). Together with Tenet Healthcare (NYSE: THC), these three companies spent the previous six quarters selling off underperforming assets in non-core markets.... Read More »
Quest Diagnostics Bought and Sold Labs in October
The Labs, MRI & Dialysis sector saw a surge of deal making in October. The sector is a conglomeration of various healthcare segments, obviously, but clinical laboratories drove the nine announced transactions. Quest Diagnostics Inc. (NYSE: DGX) announced three of those deals, first with its divestiture of its India-based medical diagnostics business, consisting of 24 diagnostic labs across the sub-continent, including a large specialized diagnostics practice with three reference labs with expertise in oncology, genomics and precision medicine. The buyer was Strand Life Sciences, a portfolio company of Quadria Capital, a clinical research and diagnostics company that combines... Read More »
Health Care M&A Deals, Week Ending October 26, 2018
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day, in the quarterly report. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Atar Capital, LLC Pathways Health and Community Support, LLC N/A Learn Behavioral Total Spectrum N/A NexPhase Capital, LP Action Behavior Centers N/A ... Read More »
OptimizeRx Adds CareSpeak Communications
OptimizeRx Corporation (NYSE: OPRX) is heavily invested in healthcare communications. Its primary business provides digital health messaging via electronic health records (EHRs), offering a direct channel for pharma companies to communicate with healthcare providers. That makes its recent $9 million acquisition of privately held CareSpeak Communications so logical. CareSpeak, based in Somerset, New Jersey, provides patient engagement, medical therapy adherence, and care coordination solutions to insurers, pharmaceutical companies, pharmacies, and specialty pharmacies. OptimizeRx’s cloud-based solution supports patient adherence to medications by providing real-time access to financial... Read More »
NeoGenomics Buys Oncology Lab Genoptix
It’s been two years since NeoGenomics, Inc. (NASDAQ: NEO) announced an acquisition, but now the time clock has been reset. On October 23rd, the cancer-focused genetic testing company made public its purchase of Genoptix, Inc., a privately held clinical oncology laboratory specializing in hematology and solid tumor testing. Genoptix has well-established relationships with community oncology practices, a sales force and pathologists that are experienced in serving oncologists, and customized reports that are considered to be the gold standard among community oncologists. Oncology practices are an important, and under-penetrated, channel for promoting NeoGenomics’ capabilities in... Read More »
Birner Dental Takes ‘Perfect Teeth’ Off the Market
It’s been a big year for mergers and acquisitions in the Physician Medical Group sector. Deal volume slowed a bit in the third quarter of 2018 compared with the previous quarter, but with two quarters of 60-plus deals, it looks like 2018 will be a record-setting year in this sector, in the 21st century, at least. Dental practices make up just 12% of the targets through late October, with 24 deals made public. (By comparison, dermatology practices are one of the hottest practice areas this year, with 40-plus deals on the books.) Most of the dental targets are standalone practices with one or two dentists. Prices aren’t usually disclosed for smaller practices, especially when the... Read More »
After a Drought, Medical Device Deals Are on the Rise
The medical device market is making a comeback in 2018, after several years of steady but uninspiring performance. Through the end of October, 103 transactions have been announced. That’s still below last year’s total, but there are two months to go in the year. Deal volume in the third quarter reached 41 transactions, up 32% compared with the previous quarter and up 78% over the year-ago period. This quarter’s deals account for 34% of the 122 deals announced in the previous 12 months. Annual deal volume hit a peak of 194 transactions in 2007, and stayed well above 165 deals per year through 2011 (175 transactions). In 2012, mergers and acquisitions topped out at 145... Read More »
Health Care M&A Deals, Week Ending October 19, 2018
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day, in the quarterly report. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Novartis AG Endocyte, Inc. $2.1 billion Roche Collaboration on cellular therapy $125 million AbbVie Inc. Collaboration targeting fibrotic diseases $100 million Sarepta Therapeutics, Inc. License to gene therapy for Sanfilippo syndrome $15 million... Read More »
Novartis Bags Cancer Researcher Endocyte
With little fanfare, Swiss drug maker Novartis AG (NYSE: NVS) bagged Endocyte, Inc. (NASDAQ: ECYT) for $2.1 billion, or $24.00 per share. The price represents a 54% premium to Endocyte’s closing price on October 17, 2018, the day before this deal was announced. Endocyte, a biopharmaceutical company based in Indiana, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses drug conjugation technology to develop targeted therapies with companion imaging agents, including one that is a potential first-in-class investigational radioligand therapy (RLT) for the treatment of metastatic castration-resistant prostate cancer. It’s currently in... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
